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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer often diagnosed late. Earlier detection is urgently needed. Pancreatic
ductal adenocarcinoma is known to associate with increased coagulation activity. We studied whether preoperative coagulation
biomarkers are useful in distinguishing PDAC from a benign tumor, intraductal papillary mucinous neoplasm (IPMN) in this
observational study. We analyzed standard clinical and coagulation variables in patients operated during 2010 and 2015 at Helsinki
University Hospital. Pancreatic ductal adenocarcinoma with preoperative coagulation variables available and no neoadjuvant
treatment or other active cancer was observed in 80 patients (stage I-III in 67 and IV in 13) and IPMN in 18 patients. Fibrinogen,
factor VIII (FVIII), carbohydrate antigen (CA) 19-9, albumin, alkaline phosphatase, and conjugated bilirubin were higher in both
stages I to III and IV PDAC compared to IPMN (P < .05). Factor VIII was highest in stage IV (P < .05). Combining these variables in a
panel increased sensitivity and specificity for PDAC. In receiver operating characteristic analysis, the area under the curve (95%
confidence interval) was 0.95 (0.90-1.00) for the panel, compared to 0.80 (0.71-0.88) for CA 19-9 alone (P < .01). In conclusion,
PDAC was associated with increased fibrinogen and FVIII. Combining these coagulation biomarkers with CA 19-9, albumin, and
alkaline phosphatase improves diagnostic accuracy.
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Background
In recent years, intensive research has targeted cancer-
associated coagulation. Cancer promotes coagulation activity
and vice versa; increased coagulation promotes cancer
growth.1 Cancer relates to increased risk of venous throm-
boembolic events (VTEs)2 and other coagulopathies.3 Venous
thromboembolic events increase mortality by 3-fold.4
Chemotherapy also increases the risk of thrombosis. Khorana
et al. introduced a risk scoring model to identify chemotherapy-
associated VTE, which includes cancer site, hemoglobin level,
platelet count, leukocyte count, and body mass index (BMI).5
This score predicts early mortality after pancreatic surgery.6
Pancreatic ductal adenocarcinoma (PDAC), representing 85%
of all pancreatic cancers,7 is one of the leading causes of
cancer-associated mortality worldwide.8 Malignancies of the
pancreas, especially adenocarcinomas, present a high risk of
thrombosis.9 Pancreatic ductal adenocarcinoma is reported to
be associated with increased circulating microparticles, factor
VIII (FVIII), and D-dimer.10,11 Non-overt coagulation activity
acts beyond clinical detection, and its role in PDAC has not
been widely studied.
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Curative treatment for PDAC requires radical
surgery.12,13 Because both surgery and malignancy are
associated with enhanced risk of thrombosis, patients with
PDAC require special attention. Owing to nonspecific
symptoms, PDAC is often diagnosed at a late stage. Tools
for early diagnosis are scarce; computed tomography (CT)
or magnetic resonance imaging (MRI) is needed, and final
diagnosis is confirmed by histopathological tissue
analysis.
Serum carbohydrate antigen (CA) 19-9, a sialylated Lewis a
antigen, is the most commonly used biomarker for PDAC.14
CA 19-9 is normally expressed by the pancreas biliary ducts,
gastrointestinal tract, endometrium and salivary glands, but
neoplastic cells increase this expression. Therein, the sensitiv-
ity and specificity for PDAC are only 70% to 90% and 68% to
91%,15 respectively, but CA 19-9 has been shown to increase as
the disease progresses.16,17 CA 19-9 may thus be more optimal
for follow-up than diagnostics.
Intraductal papillary mucinous neoplasms (IPMNs) are
benign tumors originating from the pancreatic ducts that
carry a risk of malignant transformation.18 Suspicion of
IPMN can be raised at CT scan or MRI, but the final diag-
nosis can only be confirmed by histopathology. Because of
similar preoperative psychophysiological stress known to
affect coagulation activity and cause resistance to fibrinoly-
sis,19 IPMN patients are appropriate controls for PDAC. The
influence of IPMN on coagulation has not been reported.
Because pancreatic tumor surgery is extensive, surgery for
benign tumors should be avoided, unless there is high-grade
dysplasia at biopsy or suspicion of malignant transforma-
tion. Therefore, clinical tools for distinguishing PDAC from
benign tumors are needed.
At the Helsinki University Hospital, a coagulation panel is
used to assess various coagulation disorders. The panel
includes the following: clotting times—prothrombin time
(PT) measuring vitamin K-dependent factors and activated par-
tial thromboplastin time (APTT) for the intrinsic pathway;
fibrinogen as the most abundant coagulation protein and the
source of fibrin formation; thrombin time (TT) measuring
thrombin functions on fibrinogen and circulating phospholipids
and microvesicles3,20; FVIII as a marker of liver sinusoidal
endothelium and risk of thrombosis21; antithrombin (AT) as
the key regulator of coagulation; and finally, D-dimer, the sign
of the balance between coagulation and fibrinolysis, evaluating
fibrin turnover.
Current treatments for PDAC, including surgery, che-
motherapy, and radiotherapy, increase tissue destruction,
coagulation activity, and the risk of non-overt and overt
thrombosis. The overall effects of cancer on coagulation,
while excluding the effects of treatments, are worth study-
ing in patient samples. To detect whether preoperative
biomarkers could distinguish PDAC from IPMN, we eval-
uated the effect of PDAC and IPMN on the preoperative
levels of the coagulation panel. In addition, we combined




Of 580 patients admitted to the Helsinki University Hospital for
elective pancreatic surgery during 2010 to 2015, data on pre-
operative coagulation variables were available from 318
patients. Patients with PDAC and benign IPMN were included
in this observational study. Patients who received preoperative
neoadjuvant treatment (n ¼ 43), those with another cancer
within the previous 5 years (n ¼ 21), those with tumors of
different origin (e.g., duodenal or biliary tumors, n ¼ 47), or
those with another type of pancreatic tumor (e.g., papillary
cancer) or chronic pancreatitis (n ¼ 109) were excluded due
to their possible confounding effects on coagulation activity.
The diagnosis of PDAC was confirmed by histopathology of
the surgical samples. Patients were divided into 3 groups: stage
I to III PDAC, stage IV PDAC, and IPMN. Patient character-
istics are shown in Table 1. In stage IV patients, distant metas-
tasis was unknown preoperatively, but was verified from frozen
sections early during the operation.
The study was approved by the Surgical Ethics Committee
of Helsinki University Hospital (Dnro HUS 226/E6/06, exten-
sion TMK02 §66 17.4.2013) and the National Supervisory
Authority of Welfare and Health (Valvira Dnro 1041/
06.01.03.01/2012) and was conducted according to the
Helsinki Declaration. Written informed consent was obtained
from the patients for their anonymized information to be
published in this article.
Laboratory Analyses
Blood cell counts, ABO blood groups, and plasma concentra-
tions of CA 19-9, C-reactive protein, creatinine, albumin, bilir-
ubin, alkaline phosphatase (ALP), alanine amino transferase,
and amylase were measured as part of routine preoperative
laboratory analysis for all patients. In addition to the routine
laboratory tests, we assessed the coagulation panel, including
PT, APTT, fibrinogen, TT, FVIII, AT, and D-dimer. Blood
samples were collected 1 to 10 days before surgery with 1
exception, at one month earlier. We compared the laboratory
profiles of the patients having PDAC with those of IPMN, as









Male sex (n) 31 (46%) 9 (69%) 11 (61%)
Age, years, median (range) 68 (52-81) 69 (52-78) 66 (31-80)
Antithrombotic medicationa
Enoxaparin sodium (n) 5 2 4
Acetylsalicylic acid (n) 6 2 6
Abbreviations: IPMN, intraductal papillary mucinous neoplasm; PDAC, pan-
creatic ductal adenocarcinoma.
aUsed as thromboprophylaxis for conditions of atrial fibrillation, atherothrom-
bosis, and previous venous thromboembolism.
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well as PDAC at stage I to III with stage IV. All samples were
analyzed by routine methods at the Helsinki University Hospi-
tal Laboratory, and data were gathered from laboratory records.
Coagulation Assays
Citrated 3.2% plasma was used for coagulation samples. Pro-
thrombin time was analyzed with Nycotest PT (Axis-Shield
PoC As, Oslo, Norway) and APTT with Actin FSL (Siemens
Healthcare Diagnostics, Marburg, Germany, and all following
reagents provided by Siemens are from the same source). Fibri-
nogen levels were determined using Multifibren U (Siemens
and BC Thrombin Reagent (Siemens) was used to determine
TT. Factor VIII: C (FVIII) was analyzed with a 1-stage clotting
assay (Pathromtin SL and Coagulation Factor VIII Deficient
Plasma; Siemens) and AT was measured with a chromogenic
assay (Berichrom Antithrombin III; Siemens). D-dimer levels
were measured with an immunoturbidimetric assay (Tina-
quant D-dimer; Roche Diagnostics, Mannheim, Germany).
Biomarker Panel
As the sensitivity and specificity of CA 19-9 for PDAC are not
uniform and known to vary and even miss metastatic disease,
we studied whether its diagnostic value could be improved by
combining it with other biomarkers. In a panel score combined
the biomarkers that overall distinguished both stages I to III and
IV PDAC from IPMN. The cutoff levels were chosen based on
the sensitivity and specificity of each biomarker for PDAC (see
Table 2). Each biomarker was stratified into 1 to 3 points. The
cutoff value between points 1 and 2 was determined using the
Youden J point, and the cutoff between points 2 and 3 was the
value at which the specificity was 100% for PDAC.
Statistical Analyses
We performed statistical analysis using SPSS Statistics
(v21-24; IBM Corp, Armonk, New York) and Medcalc (v18;
Ostend, Belgium). We compared the variables between the
groups using the independent-samples Kruskal-Wallis test and
the post hoc Dunn test. The w2 test was used to compare blood
ABO-type distributions. The Spearman correlation coefficient
(r) was used to identify correlations. Sensitivities and specifi-
cities were compared with receiver operating characteristic
(ROC) curves. Confidence intervals (CIs) for the sensitivity
and specificity were calculated using the Clopper-Pearson
exact binomial test and for the area under the curves (AUCs)
using binomial exact CIs. The statistical significance between
the AUCs was determined using the DeLong method. Values
presented as lower than a value (e.g., CRP <3 mg/L) were
rounded to one decimal below the next highest value.
Results
Routine PDAC-Associated Laboratory Variables
Before pancreatic surgery, CA 19-9 levels, blood cell counts,
liver enzymes, and CRP were analyzed from each patient to
determine surgical suitability, and we assessed these variables
related to the nature of the tumor and the patient groups of stage
I to III PDAC, stage IV PDAC, and IPMN. CA 19-9 was
missing from 1 patient in each group. CA 19-9, ALP,
and conjugated bilirubin were higher and albumin was lower
(P < .05; Table 3) at all stages of PDAC compared with IPMN.
Total bilirubin values were higher than in IPMN only at stage
IV PDAC (P < .05; Table 3). Importantly, CA 19-9 was below
the cutoff level in 16 (21%) patients with PDAC, of whom 3
had stage IV disease (Figure 1A). Then again, CA 19-9 was
above the cutoff level in 30% of the IPMN patients. Patients
with stage IV disease had higher leukocyte counts than IPMN
patients (P < .05; Table 3), but hemoglobin, platelet counts,
CRP, creatinine, alanine transaminase, and amylase did not
differ between the groups. In the Khorana score, patients with
PDAC receive 2 points based on tumor site, and we omitted the
points for the cancer diagnosis and screened only the hemato-
logical laboratory values and BMI. This modified Khorana
score did not distinguish PDAC from IPMN nor were there
differences between stages (data not shown).
Coagulation Biomarkers
In addition to the routine laboratory variables, the patients were
analyzed using the coagulation panel to screen whether any
coagulation abnormality was associated with PDAC. Fibrino-
gen and FVIII were significantly higher in both stages I to III
and IV PDAC compared to IPMN (P < .05; Table 3). Factor
VIII was also higher in stage IV than stage I to III PDAC









CA 19-9 (kU/L) <41 1 32 33 88
41-200 2 26 17 12
>200 3 42 50 0
FVIII (IU/dL) <183 1 24 0 83
183-267 2 55 32 17
>267 3 21 68 0
Fibrinogen (g/L) <3.6 1 13 23 72
3.6-6.3 2 81 77 28
>6.3 3 6 0 0
Albumin (g/L) >40.1 1 24 15 94
40.1-34.7 2 58 46 6
<34.7 3 18 38 0
Alkaline phosphatase
(U/L)
<88.5 1 37 38 83
88.5-106.5 2 15 8 17
>106.5 3 48 54 0
Conjugated bilirubin
(mmol/L)
<4.5 1 42 31 83
4.5-12.5 2 42 23 17
>12.5 3 16 46 0
Abbreviations: IPMN, intraductal pancreatic mucinous neoplasm; PDAC,
pancreatic ductal adenocarcinoma.
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(P < .05; Table 3, Figure 1B). Coagulation times PT, APTT,
and TT, as well as AT and D-dimer, were similar in PDAC and
IPMN, and generally within normal ranges, but close to the
reference limits (Table 3). The distribution of ABO blood
groups between PDAC and IPMN patients accorded to that
of the Finnish population (data by the Finnish Red Cross Blood
Service, not shown), and it did not correlate with FVIII levels
(data not shown).
Correlations Between the Biomarkers
Biomarkers showing a significant difference between PDAC
irrespective of stage and IPMN were subjected to bivariate anal-
ysis. Spearman correlation coefficients (r) and P values are
presented in Table 4. ALP correlated with both fibrinogen and
conjugated bilirubin in both stages I to III and IV PDAC. In stage
I to III PDAC, ALP also showed a correlation with FVIII, as did
conjugated bilirubin. Albumin depicted negative correlations
with ALP and conjugated bilirubin in both stages I to III and
IV PDAC, and also with FVIII in stage I to III and fibrinogen in
stage IV PDAC. CA 19-9 correlated with conjugated bilirubin in
stage I to III PDAC and FVIII in stage IV PDAC. In stage I to III,
FVIII and fibrinogen showed a correlation. In IPMN, there was
only a correlation between CA 19-9 and ALP and a negative
correlation between FVIII and albumin.
We also compared these 6 biomarkers with the remaining
coagulation panel markers PT, APTT, TT, AT, and D-dimer. In
stage I to III PDAC, there was a correlation between ALP and
AT (r ¼ 0.31, P ¼ .011), as well as negative correlations
between FVIII and APTT (r ¼ 0.31, P ¼ .012), and fibrino-
gen and TT (r ¼ 0.24, P ¼ .048); the latter also clearly
occurred in IPMN (r ¼ 0.73, P ¼ .001). In stage IV, fibrino-
gen correlated also with AT (r ¼ 0.62, P ¼ .023).
Biomarker Panel
As CA 19-9 is used as a regular PDAC marker and we detected
increased fibrinogen and FVIII in association with PDAC, we
next aimed at forming panels to improve the sensitivity and
specificity of these biomarkers. In addition to CA 19-9 FVIII,
fibrinogen, albumin, ALP, and conjugated bilirubin distin-
guished PDAC from IPMN in both stages I to III and IV dis-
ease. We combined these biomarkers to form a panel score
(Table 2). Using these scores, we formed 3 different panels,
which all clearly distinguished PDAC from IPMN (P < .001;
Figure 2). First, we combined all the biomarkers, and secondly
formed targeted panels.
As ALP and conjugated bilirubin may both partially reflect
the influence of bile obstruction and its patency after stent
insertion, we evaluated the panel scores also without these
Table 3. Laboratory Biomarkers Among the Patient Groups.a,b,c
Normal Range
Stage I-III
PDAC (n ¼ 67)
Stage IV PDAC
(n ¼ 13) IPMN (n ¼ 18)
P ValuesMedian (IQR)
Routine biomarkers
CA 19-9 (kU/L) <26 130 (31-709) 168 (25-711) 13 (5-35) P (IPMN vs stage IV) < .001;
P (IPMN versus stage I-III) ¼ .017
Alkaline phosphatase (U/L) 35-105 105 (74-141) 108 (69-367) 61 (53-83) P (IPMN versus stage I-III) ¼ .001;
P (IPMN versus stage IV) ¼ .004
Bilirubin (mmol/L) <20 13 (10-18) 21 (9-29) 10 (9-14) P (IPMN versus stage IV) ¼ .045
Conjugated bilirubin
(mmol/L)
0-5 5 (3-9) 11 (4-18) 3 (2-4) P (IPMN versus stage I-III) ¼ .017;
P (IPMN versus stage IV) ¼ .003
Albumin (g/L) 36-45 (40-69 years);
34-65 (>69 years)
37.7 (35.5-40.0) 36.9 (32.3-39.0) 40.9 (40.4-41.9) P (IPMN versus stage I-III) < .001;
P (IPMN versus stage IV) ¼ .001
Leukocyte count (E9/L) 3.4-8.2 7.0 (5.6-8.7) 7.3 (6.3-9.5) 5.9 (5.9-7.3) P (IPMN versus stage IV) ¼ .046
Coagulation biomarkers
PT (%) 70-130 93 (78-113) 89 (79-102) 83 (74-104) NS
APTT (s) 23-33 24 (23-26) 24 (24-26) 25 (25-28) NS
Thrombin time (s) 17-25 18 (17-19) 18 (18-19) 18 (17-20) NS
Fibrinogen (g/L) 1.7-4.0 4.6 (4.0-5.2) 5.0 (3.8-5.4) 3.3 (3.1-4.0) P (IPMN versus stage I-III) ¼ .001;
P (IPMN versus stage IV) ¼ .011
FVIII (IU/dL) 52-148 228 (184-256) 254 (231-350) 144 (133-180) P (IPMN versus stage I-III) ¼ .001;
P (IPMN versus stage IV)  .001;
P (stage I-III vs IV) ¼ .049
Antithrombin (%) 84-108 102 (94-119) 104 (97-120) 106 (98-116) NS
D-dimer (mg/L) <0.5 0.3 (<0.2-0.5) 0.3 (<0.2-0.7) <0.2 (<0.2-0.3) NS
Abbreviations: CA ¼ carbohydrate antigen, NS ¼ not significant; APTT, activated partial thromboplastin time; FVIII, factor VIII; IPMN, intraductal pancreatic
mucinous neoplasm; PT, prothrombin time.
aP Values were obtained by Kruskal-Wallis tests with post hoc Dunn test.
bProthrombin time (%) refers to PT in seconds as related to normal healthy laboratory controls. Seventeen IPMN patients had antithrombin levels available.
cP > .05
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markers of bile. The slope of the ROC curve was the steepest
when conjugated bilirubin was excluded. Including CA 19-9,
ALP, and albumin together with coagulation markers fibrino-
gen and FVIII into our final panel, the AUC improved to 0.95
(95% CI: 0.89-0.99) in comparison with 0.80 (0.71-0.88) for
CA 19-9 alone (P ¼ .002; Figure 3).
Discussion
The aim of our observational study was to assess whether
PDAC, a highly thrombogenic cancer, is preoperatively dis-
tinguishable from benign IPMN by analyzing coagulation
variables and whether the diagnostic value of CA 19-9
improves by combining it with coagulation variables. We
found that, together with CA 19-9, the biomarkers of coagula-
tion (fibrinogen and FVIII), ALP, and albumin best distin-
guished PDAC from benign IPMN, irrespective of stage.
Combining them to form a panel score clearly improved the
diagnostic accuracy. We also found that high circulating
FVIII levels were linked to distant metastasis, while FVIII
and fibrinogen overall were elevated in PDAC. These find-
ings add to the evidence that coagulation activity integrates
with pancreatic cancer and its progression.10 They even raise
the question of whether CA 19-9 is directly linked to coagula-
tion activity in pancreatic cancer.
CA 19-9 is the most commonly used tumor marker in PDAC
diagnostics and monitoring of cancer progression and treat-
ment.14 In our study, the sensitivity of CA 19-9 for PDAC was
80% and the specificity 71%, which lie within the previously
reported margins of sensitivity 70% to 90% and specificity
68% to 91%.15 However, almost one-third of the patients with
PDAC had normal CA 19-9 values. As CA 19-9 is a sialylated
Lewis a blood group antigen, patients lacking the Lewis gene
(approximately 6% of the Caucasians22) do not express CA
19-9,23 decreasing its sensitivity. CA 19-9 has been reported
to correlate with tumor stage16,17; however, there were no dif-
ferences in CA 19-9 levels between stage I to III and IV PDAC
prior to surgery.
Cancer cells use sialylated structures, that is, sialyl Lewis a,
to bind to the endothelium, one of the key mechanisms of
metastasis.24 Endothelium cancer cell adhesion may activate
coagulation. von Willebrand factor (VWF) is released from the
endothelium, and it carries FVIII in the circulation. When not
bound to VWF, FVIII disseminates quickly. The high levels of
FVIII in patients with PDAC reflect endothelial activation and/
or enhanced angiogenesis and perhaps also reduced clearance
by the liver.25 Since CA 19-9 is a sialylated Lewis antigen, it
may itself modify cellular adhesion and coagulation activity.
We found that FVIII activity was higher in PDAC than in
IPMN. Factor VIII levels increase due to multiple stimuli, such
as stress and acute phase response.21,26 However, the difference
in FVIII levels seems to be linked to malignancy rather than
inflammation or stress since emotional stress preoperatively is
the same in both PDAC and IPMN. Many reports have referred
to elevated FVIII in VTE and PDAC,27,28 but as our patients
did not have symptomatic preoperative VTEs, a broader asso-
ciation between FVIII and PDAC can be suggested.
Fibrinogen is a crucial substrate of the coagulation cascade.
High circulating fibrinogen levels have been shown to associate
with malignancy and metastasis.29-31 In our study, fibrinogen
was higher in PDAC than IPMN, supporting the link between
malignancy and fibrinogen. However, fibrinogen was not higher
in patients with distant metastasis in comparison with locore-
gional disease, and thus, our preoperative study did not confirm
previous reports on its link with metastasis. Higher fibrinogen
levels have been shown to distinguish high risk (high-grade and
invasive IPMN) from low risk (low-grade and borderline)
IPMN.32 In our study, we did not have high-risk IPMN patients,
Figure 1. Distribution of the biomarkers (A) carbohydrate antigen
(CA) 19-9 and (B) factor VIII (FVIII) in different patient groups. The
boxes show the median and the interquartile range, the whiskers rep-
resent the extremes, and outliers are presented as circles. The dotted
line represents normal reference values. P values were obtained by
Kruskal-Wallis test, after implementing post hoc Dunn test,
*P < .05, **P < .01, ***P < .001 Abbreviations: PDAC, pancreatic ductal
adenocarcinoma; IPMN intraductal papillary mucinous neoplasm
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but we observed significant differences between fibrinogen lev-
els in benign versus malignant disease.
Fibrin turnover is enhanced in cancer overall,33-37 includ-
ing PDAC.11,33,38 Sun et al. concluded that higher pretreat-
ment levels of D-dimer in PDAC predict advanced tumor
stage and metastasis.11 In our study, however, D-dimer did
not differ between PDAC and IPMN or between stage IV and
stage I to III PDAC. D-dimer values may vary based on
patient age,39 and also on the analysis method used; thus,
direct comparison between laboratories is not valid.40 In addi-
tion, the regulation of fibrinolysis may vary among patients
with cancer.
Albumin was lower in PDAC than in IPMN, reflecting
increased permeability and possibly leakage of coagulation
factors into tissue. Low albumin coincides with VTE and
mortality in patients with cancer.41 Albumin showed a negative
correlation with fibrinogen in stage IV PDAC and FVIII in
stage I to III PDAC, supporting the link between low albumin
and increased coagulation activity. Conjugated bilirubin and
ALP were higher in PDAC than in IPMN. Most of the PDAC
tumors reside in the head of pancreas, often obstructing the bile
duct; preoperative bile duct stent insertion may therefore have
confounded these results. However, high ALP may also be
linked to coagulation. Alkaline phosphatase is an active
exopolyphosphatase capable of degrading circulating
polyphosphate.42 Because polyphosphates importantly modu-
late coagulation and fibrinolysis,43 they may provoke ALP
generation in PDAC. We also noticed a positive correlation
between ALP and FVIII as well as with fibrinogen, which
supports the contribution of this exopolyphosphatase.
Table 4. Spearman Correlation Between the Biomarkers Showing Significant Differences Between PDAC and IPMN.
CA 19-9 FVIII Fibrinogen Albumin ALP
Conjugated
Bilirubin
Stage I-III CA 19-9 r (SE) 1.000
P
FVIII r (SE) 0.205 (0.115) 1.000
P .098
Fibrinogen r (SE) 0.096 (0.130) 0.314a (0.115) 1.000
P .442 .010
Albumin r (SE) 0.215 (0.126) 0.511a (0.090) 0.160 (0.126) 1.000
P .085 .000 .198
ALP r (SE) 0.010 (0.129) 0.354a (0.107) 0.372a (0.117) 0.280b (0.118) 1.000
P .939 .003 .002 .023
Conjugated bilirubin r (SE) 0.328a (0.108) 0.523a (0.094) 0.069 (0.128) 0.263b (0.123) 0.365a (0.115) 1.000
P .007 .000 .582 .033 .002
Stage IV CA 19-9 r (SE) 1.000
P
FVIII r (SE) 0.601b (0.211) 1.000
P .039
Fibrinogen r (SE) 0.131 (0.354) 0.393 (0.279) 1.000
P .685 .185
Albumin r (SE) 0.007 (0.266) 0.413 (0.250) 0.634b (0.172) 1.000
P .983 .161 .020
ALP r (SE) 0.077 (0.339) 0.374 (0.275) 0.695a (0.205) 0.703a (0.136) 1.000
P .812 .208 .008 .007
Conjugated bilirubin r (SE) 0.063 (0.253) 0.351 (0.237) 0.541 (0.216) 0.863a (0.085) 0.739a (0.098) 1.000
P .845 .240 .056 .000 .004
IPMN CA 19-9 r (SE) 1.000
P
FVIII r (SE) 0.225 (0.226) 1.000
P .385
Fibrinogen r (SE) 0.188 (0.245) 0.124 (0.272) 1.000
P .469 .623
Albumin r (SE) 0.453 (0.241) 0.507b (0.191) 0.283 (0.283) 1.000
P .068 .032 .255
ALP r (SE) 0.486b (0.198) 0.247 (0.250) 0.241 (0.270) 0.270 (0.249) 1.000
P .048 .323 .335 .278
Conjugated bilirubin r (SE) 0.180 (0.244) 0.253 (0.274) 0.057 (0.249) 0.161 (0.260) 0.314 (0.220) 1.000
P .488 .312 .821 .523 .204
Abbreviations: ALP, alkaline phosphatase; CA, carbohydrate antigen; FVIII, factor VIII; IPMN, intraductal papillary mucinous neoplasm; PDAC, pancreatic ductal
adenocarcinoma; r, Spearman correlation coefficient; SE, standard error.
aCorrelation is significant at the P < .01 level.
bCorrelation is significant at the P < .05 level.
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The modified Khorana score did not correlate with the
biomarkers or cancer stage in our pre-diagnostic study. Non-
blood type O has been reported as a risk factor for PDAC44
and of VTE.45 O blood types associate with low FVIII and
VWF levels. However, the blood type did not contribute to
our results.
We noticed correlations between the variables that distin-
guished PDAC from IPMN, suggesting that the variables
could be linked to each other. As the diagnostic potential of
CA 19-9 needs to be improved, and based on correlations with
the other markers, we decided to combine them in a panel
score. The panel score initially included CA 19-9, combined
with coagulation variables fibrinogen and FVIII, as well as
albumin, conjugated bilirubin, and ALP. High scores of this
panel strongly coincided with PDAC compared with IPMN. In
comparison with CA 19-9 alone, the sensitivity of the panel
improved. As both conjugated bilirubin and ALP can be con-
founded by the bile obstruction or stent placement, we wanted
to determine their role in the panel. Conjugated bilirubin in
the panel without ALP seemed to have the highest AUC;
however, the slope was the steepest at the beginning of the
curve, when conjugated bilirubin was excluded, but ALP was
included. Again, the proposed links between ALP and coagu-
lation suggest that ALP could be preferred in the panel instead
of conjugated bilirubin. Larger studies are needed to assess
whether these panels will assist in clinical practice to distin-
guish metastasized from local cancer.
Figure 2. Biomarker panel scores of the patient groups with carbo-
hydrate antigen (CA) 19-9, fibrinogen, factor VIII (FVIII), albumin, alka-
line phosphatase (ALP), and bilirubin conjugates (A); CA 19-9,
fibrinogen, FVIII, albumin, and ALP (B); CA 19-9, fibrinogen, FVIII,
albumin, and bilirubin conjugates (C). The boxes show the median and
the interquartile range, the whiskers represent the extremes, and the
circles the outliers. P values were obtained by Kruskal-Wallis test, using
post hoc Dunn test, ***P < .001. Abbreviations: PDAC, pancreatic
ductal adenocarcinoma; IPMN intraductal papillary mucinous neoplasm
Figure 3. Receiver operating characteristic (ROC) curve of the panel
scores. The state variable was pancreatic ductal adenocarcinoma
(PDAC) diagnosis, irrespective of the stage. The area under the curve
(AUC; 95% confidence interval [CI]) was 0.95 (0.90-1.00) for the panel
including carbohydrate antigen (CA) 19-9, fibrinogen, factor VIII
(FVIII), albumin, and alkaline phosphatase (ALP). For the biomarkers
alone, the AUC (95% CI) were as follows: 0.80 (0.71-0.88) for CA 19-
9, 0.78 (0.68-0.86) for fibrinogen, 0.79 (0.70-0.87) for FVIII: C, 0.18
(0.11-0.27) for albumin, and 0.79 (0.70-0-89) for ALP. The AUCs were
calculated for the patients with all available panel biomarkers.
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The limitations of our study include the inclusion of patients
at different stages of their disease and the small numbers of
patients in the subgroups. However, the larger stage I to III
PDAC group (n ¼ 67) provided representative data of links
within coagulation and PDAC, and patients were in a
treatment-naive state at the time of preoperative sample collec-
tion. A minority of the patients used anticoagulants or other
drugs, which may have confounded the data. Another limita-
tion of this study is the lack of VWF levels and microvesicle
data analysis. In future studies, their roles in this predictive
panel should be investigated.
Conclusions
In summary, our study supports the role of coagulation invol-
vement in PDAC, FVIII, and fibrinogen in particular, among
others. A combination panel including CA 19-9, FVIII, fibri-
nogen, albumin, and ALP deserves further clinical validation as
a diagnostic tool and disease severity marker in pancreatic
cancer. We have begun to gather data in a multicenter study
to validate these results and examine the role of this panel and
beyond in predicting early mortality after PDAC surgery.
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